Changes in medication management after a diagnosis of cancer among medicare beneficiaries with diabetes

Journal of Oncology Practice

Volumn 11, Issue 6, 2015, Pages 429-434

  Stuart, Bruce C ^a   Davidoff, Amy J ^b   Erten, Mujde Z ^b  

^a UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

^b YALE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA GLUCOSIDASE INHIBITOR; AMYLIN DERIVATIVE; ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCAGON LIKE PEPTIDE 1 DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METFORMIN; ORAL ANTIDIABETIC AGENT; RENIN INHIBITOR; SULFONYLUREA DERIVATIVE; ANTIDIABETIC AGENT;

ARTICLE; CANCER DIAGNOSIS; CANCER SURVIVOR; CONTROLLED STUDY; DIABETES MELLITUS; EVIDENCE BASED MEDICINE; FEMALE; HUMAN; LIFE EXPECTANCY; LONG TERM SURVIVAL; LOWEST INCOME GROUP; MAJOR CLINICAL STUDY; MALE; MEDICARE; MEDICATION COMPLIANCE; MEDICATION THERAPY MANAGEMENT; RANDOM SAMPLE; AGED; NEOPLASMS; STATISTICS AND NUMERICAL DATA; UNITED STATES; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; DIABETES MELLITUS; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPOGLYCEMIC AGENTS; MALE; MEDICARE PART D; MEDICATION ADHERENCE; NEOPLASMS; UNITED STATES;

EID: 84947264402     PISSN: 15547477     EISSN: 1935469X     Source Type: Journal    
DOI: 10.1200/JOP.2014.003046     Document Type: Article

References (23)

1. American Cancer Society: Cancer Facts & Figures 2012. Atlanta, GA, American Cancer Society, 2012
2. Yancik R, Havlik RJ, Wesley M.N., et al: Cancer and comorbidity in older patients: A descriptive profile. Ann Epidemiol 6:399-412, 1996
3. Anvit T, Holtedahl KA, Mikalsen H: When patients have cancer, they stop seeing me: The role of the general practitioner in early follow-up of patients with cancer-a qualitative study. BMC Fam Pract 7:19, 2006
4. Stavrou EP, Buckley N, Olivier J., et al: Discontinuation of statin therapy in older people: Does a cancer diagnosis make a difference? An observational cohort study using data linkage. BMJ Open 2:E000880, 2012
5. Bayliss EA, Bronsert MR, Reifler L.M., et al: Statin prescribing patterns in a cohort of cancer patients with poor prognosis. J Palliat Med 16:412-418, 2013
6. American Diabetes Association: Statistics about Diabetes. www.diabetes.org/diabetes-basics/statistics/
7. De Bruijn K.M., Arends LR, Hansen B.E., et al: Systematic review and metaanalysis of the association between diabetes mellitus and incidence and mortality in breast and colorectal cancer. Br J Surg 100:1421-1429, 2013
8. Lai GY, Park Y, Hartge P., et al: The association between self-reported diabetes and cancer incidence in the NIH-AARP diet and health study. J Clin Endocrinol Metab 98:E497-E502, 2013
9. Orgel E, Mittelman SD: The links between insulin resistance, diabetes, and cancer. Curr Diab Rep 13:213-222, 2013
10. Giovannucci E, Harlan DM, Archer M.C., et al: Diabetes and cancer: A consensus report. Diabetes Care 33:1674-1685, 2010
11. Vander Heiden M.G., Cantly LC, Thompson CB: Understanding the Warburg effect: The metabolic requirements of cell proliferation. Science 324:1029-1033, 2009
12. Kourelis TV, Siegel RD: Metformin and cancer: New applications for an old drug. Med Oncol 29:1314-1327, 2011
13. Snyder CF, Frick KD, Herbert R.J., et al: Preventive care in prostate cancer patients: Following diagnosis and for five-year survivors. J Cancer Surviv 5:283-291, 2011
14. Snyder CF, Frick KD, Kantsiper M.E., et al: Prevention, screening, and surveillance care for breast cancer survivors compared with controls: Changes from 1998 to 2002. J Clin Oncol 27:1054-1061, 2009
15. Snyder CF, Frick KD, Herbert R.J., et al: Quality of care for comorbid conditions during the transition to survivorship: Differences between cancer survivors and non-cancer controls. J Clin Oncol 31:1140-1148, 2013
16. American Diabetes Association: Standards of medical care in diabetes. Diabetes Care 31:S12-S54, 2008 (suppl 1)
17. Buccaneer Computer Systems and Services: Chronic Condition Data Warehouse Medicare Administrative Users Guide, Version 2.0. Marchs 2013. www.ccwdata.org/cs/groups/public/documents/document/ccw-userguide.pdf
18. Nau DP: Proportion of days covered (PDC) as the preferred method of measuring medication adherence. www.pqaalliance.org/images/uploads/files/PQA%20PDC%20vs%20%20MPR.pdf
19. Calip GS, Hubbard RA, Stergachis A, et al: Adherence to oral diabetes medications and glycemic control during and following breast cancer treatment. Pharmacoepidemiol Drug Saf 24:75-85, 2015
20. Calip GS, Boudreau DM, Loggers ET: Changes in adherence to statins and subsequent lipid profiles during and following breast cancer treatment. Breast Cancer Res Treat 138:225-233, 2013
21. Zanders MM, Haak HR, van Herk-Sukel MP, et al: Impact of cancer on adherence to glucose-lowering drug treatment in individuals with diabetes. Diabetologia [epub ahead of print on February 1, 2015]
22. Miller GE, Sarpong EM, Hill SC: Does increased adherence to medications change health care financial burdens for adults with diabetes? J Diabetes [e-pub ahead of print March 26, 2015]
23. Cooper GS, Yuan Z, Stange K.C., et al: The sensitivity of Medicare claims data for case ascertainment of six common cancers. Med Care 37:436-444, 1999